Several factors influenced attrition in a population-based elderly cohort: Neurological disorders in Central Spain Study

Vega, Saturio; Benito‐León, Julián; Bermejo‐Pareja, Félix; Medrano, María; Vega-Valderrama, Luisa M.; Rodríguez, Cilia; Louis, Elan D.

doi:10.1016/j.jclinepi.2009.03.005

Cited by 87 publications

(98 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, only 77% of participants were successfully followed up, and a few baseline characteristics were found different comparing those lost to follow-up with all eligible participants, including more urban residents, and high levels of educational attainment, family income, and plasma triglycerides (13). Nevertheless, the follow-up rate was comparable to other prospective studies conducted in comparable age-groups (44,45). Second, the diagnosis of diabetes in the current study was based on either selfreport, taking diabetes medications, or a single fasting glucose, which did not constitute a rigorous evaluation for the presence or absence of diabetes.…”

Section: Discussionmentioning

confidence: 87%

Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study

et al. 2016

View full text Add to dashboard Cite

OBJECTIVEAcylcarnitines were suggested as early biomarkers even prior to insulin resistance in animal studies, but their roles in predicting type 2 diabetes were unknown. Therefore, we aimed to determine whether acylcarnitines could independently predict type 2 diabetes by using a targeted metabolic profiling approach. RESEARCH DESIGN AND METHODSA population-based prospective study was conducted among 2,103 communityliving Chinese individuals aged 50-70 years from Beijing and Shanghai with a mean follow-up duration of 6 years. Fasting glucose, glycohemoglobin, and insulin were determined at baseline and in a follow-up survey. Baseline plasma acylcarnitines were profiled by liquid chromatography-tandem mass spectrometry. RESULTSOver the 6-year period, 507 participants developed diabetes. A panel of acylcanitines, especially with long chain, was significantly associated with increased risk of type 2 diabetes. The relative risks of type 2 diabetes per SD increase of the predictive model score were 2.48 (95% CI 2.20-2.78) for the conventional and 9.41 (95% CI 7.62-11.62) for the full model including acylcarnitines, respectively. Moreover, adding selected acylcarnitines substantially improved predictive ability for incident diabetes, as area under the receiver operator characteristic curve improved to 0.89 in the full model compared with 0.73 in the conventional model. Similar associations were obtained when the predictive models were established separately among Beijing or Shanghai residents. CONCLUSIONSA panel of acylcarnitines, mainly involving mitochondrial lipid dysregulation, significantly improved predictive ability for type 2 diabetes beyond conventional risk factors. These findings need to be replicated in other populations, and the underlying mechanisms should be elucidated.The escalating global epidemic of type 2 diabetes has contributed considerably to socioeconomic burdens in both developed and developing countries (1). To understand biological mechanisms and improve clinical predictions, it is essential to identify novel biomarkers to enhance the capability to predict early pathophysiological changes (2). As a largely preventable disease, early prediction is the key to control the epidemic trend of type 2 diabetes, particularly in those countries with

show abstract

Section: Discussionmentioning

confidence: 87%

Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Data for these analyses were derived from the Neurological Disorders in Central Spain (NEDICES) study, a longitudinal, population-based survey of the prevalence, incidence, and determinants of major ageassociated conditions of the elderly, including Parkinson's disease, essential tremor, stroke, and dementia [16][17][18][19][20][21][22][23][24][25]. Detailed accounts of the study population and sampling methods have been published [23][24][25].…”

Section: Study Populationmentioning

confidence: 99%

“…Detailed accounts of the study population and sampling methods have been published [23][24][25]. The study population was composed of elderly subjects, 65 years old, living in three communities in central Spain (Las Margaritas, Lista, and Arévalo).…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Statins and Cognitive Functioning in the Elderly: A Population-Based Study

Benito-León

Louis

Vega³

et al. 2010

JAD

Self Cite

View full text Add to dashboard Cite

Abstract. In a 2009 Cochrane review, the authors concluded that there is good evidence that statins, given in late life to people at risk of vascular disease, have no effect in preventing Alzheimer's disease or dementia. A related issue, which remains unclear, is whether statins improve cognitive function. While some studies have shown a beneficial effect of statins on cognitive function, others have observed mild detrimental effects on cognition. Our aim was to assess cognitive function in community-dwelling elderly participants treated with statins compared with their untreated counterparts (i.e., controls) living in the same population. 137 population-dwelling participants who were receiving statins and 411 matched controls age 65 years (median = 72 years) in central Spain (the Neurological Disorders in Central Spain [NEDICES] study) underwent a neuropsychological assessment, including tests of global cognitive performance, frontal-executive function, verbal fluency, and memory. Median duration of statin treatment was 2 years. Of 137 participants receiving statins, 53 (38.7%) were taking pravastatin, 38 (27.7%) simvastatin, 37 (27.0%) lovastatin, 6 (4.4%) fluvastatin, and 3 (2.2%) atorvastatin. Although initial univariate analyses indicated some differences, after adjusting for age, gender, education, depressive symptoms, premorbid intelligence, medications that potentially affect cognitive function, and blood cholesterol levels, statin users and controls performed similarly on all neuropsychological tests. In this population-based sample, elderly participants treated with statins and untreated controls performed similarly in all tested cognitive areas. These results do not support a positive benefit of statins on cognition.

show abstract

“…[10][11][12][13][14][15][16][17][18][19][20] A detailed account of the NEDICES study population and sampling methods has been published. [21][22][23] The survey area consisted of 3 communities: (1) Las Margaritas (approximately 14,800 inhabitants), a working-class neighborhood in Getafe (Greater Madrid); (2) Lista (approximately 150,000 inhabitants), a professional-class neighborhood in the Salamanca district (Central Madrid); and (3) Arévalo (approximately 9,000 inhabitants), an agricultural zone of Arévalo County (located 125 km northwest of Madrid). Updated lists of residents were generated from population registers.…”

mentioning

confidence: 99%

Long sleep duration in elders without dementia increases risk of dementia mortality (NEDICES)

et al. 2014

View full text Add to dashboard Cite

Objective: To determine in a population-based study whether long sleep duration was associated with increased risk of dementia mortality. Methods:In this prospective, population-based study of 3,857 people without dementia aged 65 years and older (NEDICES [Neurological Disorders in Central Spain]), participants reported their daily sleep duration. The average daily total sleep duration was grouped into 3 categories: #5 hours (short sleepers), 6-8 hours (reference category), and $9 hours (long sleepers). Communitydwelling elders were followed for a median of 12.5 years, after which the death certificates of those who died were examined.Results: A total of 1,822 (47.2%) of 3,857 participants died, including 201 (11.0%) deaths among short sleepers, 832 (45.7%) among long sleepers, and 789 (43.3%) among those participants in the reference category. Of 1,822 deceased participants, 92 (5.1%) had a dementia condition reported on the death certificate (49 [53.3%] were long sleepers, 36 [39.1%] reported sleeping between 6 and 8 hours, and 7 [7.6%] were short sleepers). In an unadjusted Cox model, risk of dementia-specific mortality was increased in long sleepers (hazard ratio for dementia mortality in long sleepers 5 1.58, p 5 0.04) when compared with the reference group. In a Cox model that adjusted for numerous demographic factors and comorbidities, the hazard ratio for dementia mortality in long sleepers was 1.63 (p 5 0.03).Conclusions: Self-reported long sleep duration was associated with 58% increased risk of dementia-specific mortality in this cohort of elders without dementia. Future studies are required to confirm these findings.

show abstract

Several factors influenced attrition in a population-based elderly cohort: Neurological disorders in Central Spain Study

Cited by 87 publications

References 35 publications

Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study

Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study

Statins and Cognitive Functioning in the Elderly: A Population-Based Study

Long sleep duration in elders without dementia increases risk of dementia mortality (NEDICES)

Contact Info

Product

Resources

About